(Sharecast News) - AstraZeneca reported first-half total revenue of $30.7bn on Monday, up 9%, while core earnings per share increased 12% to $5.21 as double-digit growth in its Oncology and Rare Disease businesses offset headwinds from Farxiga's US loss of exclusivity and China's volume-based procurement programme.
The FTSE 100 drugmaker increased...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE